Connie Goodman-Milone to be Featured on CUTV News Radio

MIAMI, FLORIDA, UNITED STATES, March 5, 2018 /EINPresswire.com/ — “It is so wonderful to know there’s a place for caring people in this world.” This is what Connie Goodman-Milone, a highly regarded writer, Miami writing mentor and philanthropist, had to say about receiving a Marquis Who’s Who Humanitarian Award in 2017. It is one of the two she is proudest of in her string of accolades. The other was for Bereavement Volunteer of the Year, from VITAS Healthcare, bestowed on her in 2001, for her outstanding emotional and spiritual support of persons going through the hospice and grieving process (at a most crucial time of loss in American history.)

Connie has been oft-recognized for her work–as a frequent contributor of letters to the editor to the Miami Herald. Also for running groups, projects, and contests as community relations director of the South Florida Writer’s Association, and director of the Junior Orange Bowl Creative Writing Committee. She is an award-winning wordsmith who favors Haiku and free verse lyrical poetry, and was published in Poets Corner, Healthy Stories, Florida State Poets Association Anthology, Author’s Voice and other media.

But there is another, even more noble side to her; Connie is a credentialed social worker, and a compassionate supported for those who have experienced the pain of loss. She understands the emotions and needs of patients and the destruction of Cancer firsthand, since she stood faithfully by her mother’s side throughout mom’s battle with the disease. Sadly, mom passed only three months after she gave Connie the most beautiful wedding in Philadelphia.

Connie became a hospice volunteer at the VITAS inpatient unit at North Shore Hospital in Miami, and was so attuned at understanding matters, that patients and family members welcomed Connie’s support. She has since become a cherished volunteer for VITAS Healthcare. She is incredibly civic-minded and serves as a field partner for Doctors Without Borders, a champion for the American Red Cross and a patron of many non-profit organizations focused on wildlife and human rights.

Connie’s great loves have converged in her most meaningful initiative, an in-development book she is compiling with Jonathan Rose. It is known as The Bereavement Poetry Project and will be a two-volume anthology with a bereavement-themed name. The book will feature writers, at all levels and from all walks of life, who have experienced loss. Connie believes poetry is a healing art, and a great tool for coping with the death of a loved one.

Connie has lived in Miami since 1997 and is a known entity there. She is recognized as much for her gun violence protection and baseball writing pieces as her work for the local Veterans Creative Arts Festival. Help celebrate her special spirit and accomplishments during her two radio interviews.

CUTV News will feature writer and volunteer Connie Goodman-Milone in interviews with Doug Llewelyn on March 7th at 2:00pm EST and with Jim Masters on 14th at 2:00pm EST.

Listen to the shows on BlogTalkRadio.

If you have questions for our guest, please call (347)996-3389.

For more information on Connie’s writing, volunteer work and awards, visit her website
www.conniegoodman-milone.com and check out the press or civic sections.

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

Jenny Deady Rising Star Practitioner to be Featured on CUTV News Rad

NEW YORK, NEW YORK, UNITED STATES, March 5, 2018 /EINPresswire.com/ — Trees shed their leaves and grow new ones for a reason. People, on the other hand, tend to hold on to everything and keep it inside. Mindfulness and energy healing can help you to release thoughts and emotions that no longer serve us. A dream of spring.

Jenny Deady is an energy healer specializing in The Rising Star Healing System. The Rising Star is an extraordinarily powerful energy healing modality that directs energy through a client’s chakra system.

“Our best healer is ourselves,” says Jenny. “The Rising Star is probably the most complementary healing system in the world. It raises the vibration of our energy field and the field around every living thing. It's much more powerful in how it can move you forward and heal.”

Science has proven that everything is energy. With both humans and animals, energy fields operate inside and outside our bodies. All disease begins on an energetic level. In fact, many of our physical ailments are the result of something that's askew in our energy systems and in our energy field.

Rising Star directs the energy from source to the source within the client. What happens next can only be described as a transformation.

“I had always been someone who suffered from anxiety, worry, stress, a lot of irrational fear,” recalls Jenny. “I went for the Rising Star healing session myself and I literally could feel everything shift and change. My perception started to change. I started to feel better. A lot of blocks that were holding me back were released. I felt lighter. I knew immediately that this was amazing. I basically was transformed by this system. I haven't looked back.”

Today, Jenny is a true advocate for wellness through alternative healing modalities. She is also a practitioner of Prema Birthing, the sister healing system of The Rising Star, that breaks the cords that connect us with agreements we made before we came into this world. With Prema Birthing, you almost feel like you're being reborn, but reborn into your true self, into love, so you can start anew.

“I believe we need to work together with Western or allopathic medicine to heal everybody on a holistic level,” says Jenny. “I want to introduce people to methods that actually benefit them or heal them and alleviate some of their problems before they need to be further treated or take medication. I want to bring greater awareness to this modality and how helpful and beneficial it can be, so people can see it for themselves and know that there are alternatives, there are options.”

CUTV News Radio will feature Jenny Deady in an interview with Jim Masters on March 7th at 4pm EST.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389.

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

Cary Skin Center Pinehurst Announces New PA Associate

Shannon Craven, P.A.

Her experience and expertise will be a great resource for the patients in Pinehurst

We are proud to have Shannon join our practice, Cary Skin Center Pinehurst.”

— Robert E. Clark, MD, PhD

PINEHURST, NORTH CAROLINA, USA, March 5, 2018 /EINPresswire.com/ — Cary Skin Center is proud to announce the appointment of Shannon Craven, PA-C as a Physician Assistant for their office in Pinehurst, N.C. Mrs. Craven is an experienced Dermatologic Physician Assistant and is a professional with advanced education and national certification.
Shannon Craven joins Cary Skin Center with a Master of Health Science Physician Assistant studies at Mercer University, Atlanta, GA. and a Masters of Biological Science at Clemson University, Clemson, SC. She is a graduate of Francis Marion University, Florence, SC.
Mrs. Craven has had experience as a Molecular Research Associate at Greenwood Genetic Center. She was also a teaching assistant at Clemson University where she was an instructor in a Science Inquiry Lab.
Mrs. Craven is a member of the Society of Dermatology Physician Assistants. Other memberships include the American Academy of Physician Assistants, Godsey-Matthews Society and the North Carolina Medical Society.
“We are proud to have Shannon join our practice, Cary Skin Center Pinehurst,” said, Robert E. Clark, MD, PhD, founder of Cary Skin Center, “Her experience and expertise will be a great resource for the patients in Pinehurst and surrounding areas.”
Outside of work, Mrs. Craven enjoys spending time with her husband and two children. Active in hiking, she has hiked the Foothills Trail in South Carolina and hiked some 523 miles of the Appalachian Trail.
Cary Skin Center has offices in Cary and Pinehurst, North Carolina. Led by Robert E. Clark, MD, PhD and Timothy C. Flynn, MD, Cary Skin Center is dedicated to the treatment of skin cancer.
About Cary Skin Center:
In 1998, Dr. Clark established the Cary Skin Center, a state-of-the-art outpatient surgical center specializing in Mohs Micrographic Surgery for the removal of skin cancer. Dr. Flynn joined the Cary Skin Center in 2001 and together they have successfully treated over 50,000 patients in the Triangle and surrounding areas.
Because Mohs surgery is a highly complex and sophisticated surgical method, it requires extensive training. Dr. Clark, Dr. Flynn, Dr. Ayli and Dr. Ingraffea completed 1-2 year intensive training programs, including complex surgical cases and advanced reconstruction to become Fellows of the American College of Mohs Surgery. In addition, they offer over 60 years of combined Mohs surgery experience.
For more information contact:
Parker Eales
Administrator
Cary Skin Center
919-303-4053 (office)
www.caryskincenter.com

Parker Eales
Cary Skin Center
919-303-4053
email us here

INTRODUCTION TO CARY SKIN CENTER


Source: EIN Presswire

Market Overview of Diabetic Nephropathy pipeline Landscape

Global Diabetic Nephropathy Drugs and Companies Pipeline Review H1 2018

PUNE , INDIA, March 5, 2018 /EINPresswire.com/ — Summary
Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3031103-diabetic-nephropathy-pipeline-review-h1-2018

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 13, 1, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
Introduction 5
Diabetic Nephropathy – Overview 6
Diabetic Nephropathy – Therapeutics Development 7
Diabetic Nephropathy – Therapeutics Assessment 18
Diabetic Nephropathy – Companies Involved in Therapeutics Development 28
Diabetic Nephropathy – Drug Profiles 48
Diabetic Nephropathy – Dormant Projects 209
Diabetic Nephropathy – Discontinued Products 212
Diabetic Nephropathy – Product Development Milestones 213
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3031103-diabetic-nephropathy-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Cyclin Dependent Kinase 6 Market by Complete Overview for Therapeutics Development and Assessment, 2018

Cyclin Dependent Kinase 6

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Cyclin Dependent Kinase 6 – Pipeline Review, H1 2018”

Cyclin Dependent Kinase 6

Overview

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) – Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation.

It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031119-cyclin-dependent-kinase-6-cell-division-protein-kinase

 

Major Key Players:

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Cyclin Dependent Kinase 6 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Cyclin Dependent Kinase 6    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cyclin Dependent Kinase 6   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively.   

Cyclin Dependent Kinase 6 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Cyclin Dependent Kinase 6 – Competitive Analysis

Key players are making innovative developments in Cyclin Dependent Kinase 6 industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cyclin Dependent Kinase 6.

The pipeline guide reviews pipeline therapeutics for Cyclin Dependent Kinase 6 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cyclin Dependent Kinase 6 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cyclin Dependent Kinase 6 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Cyclin Dependent Kinase 6.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031119-cyclin-dependent-kinase-6-cell-division-protein-kinase

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Primary Hyperoxaluria Therapeutic and Disease Pipeline Review H1

Primary Hyperoxaluria Therapeutic Pipeline Market Review, H1 2018

PUNE , INDIA, March 5, 2018 /EINPresswire.com/ — Summary
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain and frequent urge to urinate. Treatment includes Oral preparations of phosphates and diuretics.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3031099-primary-hyperoxaluria-pipeline-review-h1-2018

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Hyperoxaluria – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 1, 1, 2 and 1 respectively.

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
– The pipeline guide reviews pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Primary Hyperoxaluria – Overview
Primary Hyperoxaluria – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Hyperoxaluria – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mechanism Of Action
R&D Progress
ALN-GO1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCR-PHXC – Drug Profile
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3031099-primary-hyperoxaluria-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Neurologists Market 2018- Global Industry Analysis, By Key Players, Segmentation, Trends And Forecast By 2023

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ — Neurologists Market 2018   

Wiseguyreports.Com Adds “Neurologists – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023” To Its Research Database.

Description: 

Neurologists Market Global Report 2018 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global neurologists market.

Description: 
Where is the largest and fastest growing market for the neurologists? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurologists market global report from the Business Research Company answers all these questions and many more. 
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider healthcare market, and compares it with other markets. 
• The market characteristics section of the report defines and explains the market. 
• The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market. 
• Market segmentations break down market into sub markets. 
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing. 
• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified. 
• The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this. 
• The neurologists market section of the report gives context. It compares the neurologists market with other segments of the neurologists market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Neurologists Market Indicators Comparison.

Request for Sample Report@ https://www.wiseguyreports.com/sample-request/2975287-neurologists-global-market-report-2018-including-clinical-neurophysiologists

Scope

Markets Covered: Clinical Neurophysiologists; Vascular Neurologists; Pain Management And Palliative Care Neurologists; Neurodevelopmental And Neuromuscular Neurology; Pediatric Neurologists

Companies Mentioned: B. BraunMelsungen AG, Stryker Corporation, Integra Life Sciences Holdings Corp., St. Jude Medical Inc., Medtronic Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Neurologists Market Indicators Comparison. 

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Complete report details @ https://www.wiseguyreports.com/reports/2975287-neurologists-global-market-report-2018-including-clinical-neurophysiologists

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

1. Neurologists Market Characteristics

2. Neurologists Market Size And Growth 

3. Neurologists Trends And Strategies;

4. Pestle Analysis 

5. Neurologists Market Customer Information;

6. Neurologists Market Regional And Country Analysis 

7. Neurologists Market Segmentation 

8. Neurologists Market Segments 

9. Global Neurologists Market Comparison With Macro Economic Factors 

10. Neurologists Market Comparison With Macro Economic Factors Across Countries 

11. Asia-Pacific Neurologists Market 

12. Western Europe Neurologists Market 

13. Eastern Europe Neurologists Market 

14. North America Neurologists Market 

15. South America Neurologists Market 

16. Middle East Neurologists Market 

17. Africa Neurologists Market 

…….

Neurologists Market Competitive Landscape 
18.1. Company Profiles 
18.2. B. BraunMelsungen AG 
      18.2.1. Overview 
      18.2.2. Products And Services 
      18.2.3. Strategy 
      18.2.4. Financial Performance 
    18.3. Stryker Corporation 
      18.3.1. Overview 
      18.3.2. Products And Services 
      18.3.3. Strategy 
      18.3.4. Financial Performance 
    18.4. Integra Life Sciences Holdings Corp. 
      18.4.1. Overview 
      18.4.2. Products And Services 
      18.4.3. Strategy 
      18.4.4. Financial Performance 
    18.5. St. Jude Medical Inc. 
      18.5.1. Overview 
      18.5.2. Products And Services 
      18.5.3. Strategy 
      18.5.4. Financial Performance 
    18.6. Medtronic Inc. 
      18.6.1. Overview 
      18.6.2. Products And Services 
      18.6.3. Strategy 
      18.6.4. Financial Performance
…….

Reasons to Purchase:

Reasons to Purchase: 
• Outperform competitors using accurate up to date demand-side dynamics information. 
• Identify growth segments for investment. 
• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. 
• Create regional and country strategies on the basis of local data and analysis. 
• Stay abreast of the latest customer and market research findings 
• Benchmark performance against key competitors. 
• Develop strategies based on likely future developments. 
• Utilize the relationships between key data sets for superior strategizing. 
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis 
• Gain a global perspective on the development of the market. 
• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Continued…..

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

RAC Gamma Serine Market Assessment by Molecule Type and Therapeutics Development, 2018

RAC Gamma Serine

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “RAC Gamma Serine – Pipeline Review, H1 2018”

RAC Gamma Serine

Overview

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

The latest report RAC Gamma Serine Threonine Protein Kinase – Pipeline Review, H1 2018, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031117-rac-gamma-serine-threonine-protein-kinase-protein-kinase

 

Major Key Players:

AstraZeneca Plc

Merck & Co Inc

Novartis AG

RAC Gamma Serine Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide RAC Gamma Serine    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for RAC Gamma Serine   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) – RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene. AKT3 regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. It plays an important role in brain development and viability of malignant glioma cells. It is required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. The molecules developed by companies in Phase II and Preclinical stages are 6 and 1 respectively.  

RAC Gamma Serine pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

RAC Gamma Serine – Competitive Analysis

Key players are making innovative developments in RAC Gamma Serine industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of RAC Gamma Serine.

The pipeline guide reviews pipeline therapeutics for RAC Gamma Serine by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in RAC Gamma Serine therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates RAC Gamma Serine therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for RAC Gamma Serine.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031117-rac-gamma-serine-threonine-protein-kinase-protein-kinase

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Tyrosine Protein Kinase CSK Market Overview by Companies, Drug Profile and Development by Companies 2018

Tyrosine Protein Kinase CSK

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tyrosine Protein Kinase CSK – Pipeline Review, H1 2018”

Tyrosine Protein Kinase CSK

Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response.

 It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031116-tyrosine-protein-kinase-csk-c-src-kinase-or

 

Major Key Players:

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Tyrosine Protein Kinase CSK Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Tyrosine Protein Kinase CSK    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tyrosine Protein Kinase CSK   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 1 respectively.  

Tyrosine Protein Kinase CSK pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Tyrosine Protein Kinase CSK – Competitive Analysis

Key players are making innovative developments in Tyrosine Protein Kinase CSK industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Tyrosine Protein Kinase CSK.

The pipeline guide reviews pipeline therapeutics for Tyrosine Protein Kinase CSK by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tyrosine Protein Kinase CSK therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tyrosine Protein Kinase CSK therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Tyrosine Protein Kinase CSK.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031116-tyrosine-protein-kinase-csk-c-src-kinase-or

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Mitogen Activated Protein Kinase 3 – Disease Assessment and Therapeutics Analysis Forecasts to 2024

Mitogen Activated Protein Kinase 3

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Mitogen Activated Protein Kinase 3 – Pipeline Review, H1 2018”

Mitogen Activated Protein Kinase 3

Overview

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Mitogen-activated protein kinase 3 is an enzyme encoded by the MAPK3 gene. It acts in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. It is activated by upstream kinases resulting in its translocation to the nucleus where it phosphorylates nuclear targets.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031115-mitogen-activated-protein-kinase-3-ert2-or-insulin

 

Major Key Players:

AGV Discovery SAS

Eli Lilly and Co

Kalyra Pharmaceuticals Inc

Kura Oncology Inc

Merck & Co Inc

Mitogen Activated Protein Kinase 3 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Mitogen Activated Protein Kinase 3    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Mitogen Activated Protein Kinase 3   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Discovery stages are 2, 3 and 3 respectively. 

Mitogen Activated Protein Kinase 3 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Mitogen Activated Protein Kinase 3 – Competitive Analysis

Key players are making innovative developments in Mitogen Activated Protein Kinase 3 industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Mitogen Activated Protein Kinase 3.

The pipeline guide reviews pipeline therapeutics for Mitogen Activated Protein Kinase 3 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Mitogen Activated Protein Kinase 3 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Mitogen Activated Protein Kinase 3 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Mitogen Activated Protein Kinase 3.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031115-mitogen-activated-protein-kinase-3-ert2-or-insulin

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire